TRexBio is a biotechnology company based in South San Francisco, CA, specializing in decoding human tissue biology to develop groundbreaking therapeutics for immune-mediated diseases. Their unique Deep Biology Platform allows them to map Treg behavior in human tissue, identifying dysregulation in disease and enabling the discovery of novel treatments.
With a focus on tissue regulation and Treg immunobiology, TRexBio leverages advanced sequencing, computational tools, and disease-relevant human assay systems to generate translatable insights and create revolutionary therapeutics. Their multidisciplinary approach combines expertise in machine learning, high-throughput -omics, translational immunology, and traditional drug discovery techniques, making them a pioneering force in the field of immune-mediated disease treatment.
Generated from the website
